Harbour BioMed resubmits BLA for batoclimab to China’s NMPA for generalized myasthenia gravis
Harbour BioMed (HKEX: 02142), a prominent global biopharmaceutical company, has announced the resubmission of the Biologics License Application (BLA) for batoclimab (HBM9161) to the National Medical Products Administration (NMPA) of China. This resubmission is a significant step toward the potential approval and commercialization of batoclimab for the treatment of generalized myasthenia gravis (gMG), a debilitating […]